Abstract
Molecular targeting drugs (MTG) have proved effective for head and neck cancer (HNC) not only in basic studies but in many clinical trials. Cetuximab, an anti-EGFR monoclonal antibody, is a key drug for regimens including MTG. However, monotherapy with cetuximab has shown limited success. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway, as has molecular crosstalk between the NFkappaB and STAT3 signaling pathways. Therefore, the combination of cetuximab with an agent that inhibits the activation of both Akt and STAT3 may overcome resistance to cetuximab in HNC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
